Stability of an extemporaneously prepared recombinant human interferon alfa-2b eye drop formulation.
暂无分享,去创建一个
[1] J. Herson,et al. Topical human fibroblast interferon for acute adenoviral conjunctivitis , 1987, Graefe's Archive for Clinical and Experimental Ophthalmology.
[2] L. Ruiz,et al. Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. , 2003, International journal of pharmaceutics.
[3] S. Clarke,et al. Pemetrexed: single-agent and combination phase I study overview. , 2002, Seminars in oncology.
[4] M. Britton. The epidemiology of mesothelioma. , 2002, Seminars in oncology.
[5] C. Karp,et al. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon α-2b , 2001 .
[6] W Wang,et al. Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.
[7] P. Cony-Makhoul,et al. Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon-Presented in part at the 38th annual meeting of the American Society of Hematology, Orlando, FL, December 6-10, 1996. , 1998 .
[8] P. Cony-Makhoul,et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. , 1998, Blood.
[9] M. Tomita,et al. Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. , 1996, Journal of pharmaceutical sciences.
[10] N. Maria,et al. The use of deferoxamine infusions to enhance the response rate to interferon‐α treatment of chronic viral hepatitis B , 1996, Journal of viral hepatitis.
[11] T. C. Barnett,et al. Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study. , 1996, Cancer biotherapy & radiopharmaceuticals.
[12] J. Pepose,et al. Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient. , 1995, Cornea.
[13] A. Deplano,et al. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. , 2008, Liver.
[14] L. Reynolds. Guidelines for the preparation of sterile ophthalmic products. , 1991, American journal of hospital pharmacy.
[15] M. Yin-Murphy,et al. Inhibition of epidemic isolates of coxsackievirus type A 24 by recombinant and natural interferon alpha and interferon beta. , 1988, Intervirology.
[16] A. Romano,et al. Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections. , 1988, Metabolic, pediatric, and systemic ophthalmology.
[17] M. Hoffman. Acute haemorrhagic conjunctivitis. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.